(2S)-3-bromo-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methylpropanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-3-bromo-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methylpropanamide
• 化学式: C₁₂H₁₀BrF₃N₂O
• 分子量: 335.12
• InChiKey: MIBXMHZCAPLLEA-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• SARMS AND METHOD OF USE THEREOF
  申请人：UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

  公开号：US20140221479A1

  公开（公告）日：2014-08-07

  This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.

  本发明涉及一种饲料组成物和通过增加瘦肉质量、减少脂肪质量和/或减少脂肪质量百分比的影响躯体成分的方法，其中包括SARM化合物。
• Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
  申请人：GTx, Inc.

  公开号：US10314807B2

  公开（公告）日：2019-06-11

  This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and/or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

  本发明涉及对受试者（例如女性受试者）乳腺癌的治疗。包括以下方法治疗转移性乳腺癌；难治性乳腺癌；AR 阳性乳腺癌；AR 阳性难治性乳腺癌；AR 阳性转移性乳腺癌；AR 阳性和 ER 阳性乳腺癌；三阴性乳腺癌；晚期乳腺癌；SERM（他莫昔芬、托瑞米芬）、芳香化酶抑制剂、palbociclib（Ibrance）、曲妥珠单抗（赫赛汀、ado-trastuzumab emtansine）、pertuzumab（Perjeta）、拉帕替尼、依西美坦（Aromasin）、贝伐珠单抗（Avastin）和/或氟维司群治疗失败的乳腺癌；或 HER2 阳性；包括向受试者施用治疗有效量的选择性雄激素受体调节剂（SARM）化合物。
• METHOD OF TREATING HER2-POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)
  申请人：GTx, Inc.

  公开号：US20170209407A1

  公开（公告）日：2017-07-27

  This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and/or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
• US9278914B2
  申请人：——

  公开号：US9278914B2

  公开（公告）日：2016-03-08
• [EN] A METHOD OF TREATING ER MUTANT EXPRESSING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)<br/>[FR] MÉTHODE DE TRAITEMENT DE CANCERS DU SEIN EXPRIMANT UN MUTANT ER AVEC DES MODULATEURS SÉLECTIFS DU RÉCEPTEUR DES ANDROGÈNES (SARM)
  申请人：ONCTERNAL THERAPEUTICS INC

  公开号：WO2020028593A9

  公开（公告）日：2021-03-18

  [EN] This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio)), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; and/or treating a subject suffering from ER mutant expressing breast cancer, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
  [FR] La présente invention concerne le traitement du cancer du sein chez un sujet, par exemple un sujet féminin. L'invention comprend des méthodes de traitement de : cancer du sein métastatique; cancer du sein réfractaire; cancer du sein AR positif; cancer du sein réfractaire AR positif; cancer du sein métastatique AR positif; cancer du sein AR positif et ER positif; cancer du sein triple négatif; cancer du sein avancé; cancer du sein pour lequel le traitement par un modulateur sélectif du récepteur des œstrogènes (SERM) (tamoxifène, torémifène, raloxifène), un agoniste de l'hormone de libération de la gonadotropine (GnRH) (goséréline), un inhibiteur de l'aromatase (AI) (létrozole, anastrozole, exémestane), un inhibiteur de la kinase 4/6 dépendant de la cycline (CDK 4/6) (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio)), un inhibiteur de mTOR (évérolimus), le trastuzumab (Herceptine, ado-trastuzumab emtansine), le pertuzumab (Perjeta), le lapatinib, le nératinib (Nerlynx), l'olaparib (Lynparza) (un inhibiteur de l'enzyme poly ADP ribose polymérase (PARP)) le bevacizumab (Avastin), et/ou le fulvestrant a échoué; la métastase chez un sujet souffrant d'un cancer du sein; HER2 positif; et/ou de traitement d'un sujet souffrant d'un cancer du sein exprimant un mutant ER, comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé modulateur sélectif du récepteur des androgènes (SARM).